Maestro adds the assistive-robotics archetype to DEPLOY's surgical cluster: it augments the surgeon (holding and positioning instruments) rather than replacing the surgeon's hands like the teleoperated da Vinci, Hugo, and Versius. Assistive-vs-replacement is the clinical-domain distinction it anchors.
✔
Its AI is shipped and cleared: ScoPilot (NVIDIA Holoscan-powered) for intraoperative scope control, FDA-cleared in 2025 with a Predetermined Change Control Plan, on top of the Maestro platform's own 510(k).
Price
No reviewed price is on record. We do not treat unverified analyst estimates as pricing data. There is no consumer price. Maestro is enterprise B2B surgical equipment sold to hospitals, so DEPLOY records zero price points rather than a consumer figure.
Availability
Internal use only
Maestro is sold to hospitals, not consumers. From Moon Surgical, it received FDA 510(k) clearance K240598 on June 5, 2024, and its ScoPilot AI software was FDA-cleared in 2025 (with a Predetermined Change Control Plan).
Real-world status
Moon Surgical's Maestro is a laparoscopic surgical-assistant platform: it holds and positions instruments and the endoscope alongside the surgeon, rather than being a full master-slave teleoperated replacement system. That makes it the assistive-laparoscopy archetype of DEPLOY's surgical cluster, editorially distinct from the replacement-robotics of Intuitive, Medtronic, and CMR. Its ScoPilot software is shipped AI (NVIDIA Holoscan-powered) for intraoperative scope control. The Maestro received FDA 510(k) clearance K240598 on June 5, 2024 (not December 2023), and ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan.
Two precision points: the Maestro 510(k) is K240598, cleared June 5, 2024 (not December 2023); and Maestro is a surgeon-assistant, not a replacement system, so it should not be read as an autonomous or master-slave surgical robot.
⊘
There is no consumer price. Maestro is enterprise B2B surgical equipment sold to hospitals, so DEPLOY records zero price points.
No⊘absence. It is enterprise B2B surgical equipment sold to hospitals; there is no consumer price.
Is the Maestro a replacement for the surgeon?
No, it is a surgical assistant🟢verified: it holds and positions instruments and the endoscope alongside the surgeon, not a full master-slave teleoperated replacement.
When was the Maestro FDA-cleared?
510(k) K240598, cleared June 5, 2024🟢verified (not December 2023). ScoPilot was FDA-cleared in 2025 with a Predetermined Change Control Plan.
What is ScoPilot?
Moon Surgical's shipped AI software (NVIDIA Holoscan-powered)🟢verified for intraoperative scope control, FDA-cleared 2025 with a PCCP.
How does Maestro compare to the rest of the cluster?
It is the assistive-laparoscopy archetype🟢verified; da Vinci, Hugo, and Versius are teleoperated replacement systems, while Maestro augments the surgeon.
Pricing and availability are tagged verified or claimed against primary sources. Manufacturer targets are reported as targets, not prices you can pay today.